Join us on January 10th at 8:00 AM EST for "Hamlet Biopharma: Innovation for the Treatment of Cancers and Infections" with Dr. Catharina Svanborg, Founder & Chairman of the Board of Hamlet BioPharma, and Marc Estigarribia, Managing Director of MSQ Ventures.
🔬 Join us to learn about groundbreaking cancer research, including the discovery of HAMLET – a new class of cancer drugs with broad effects.
Dr. Catharina Svanborg: Renowned Professor of Clinical Immunology at Lund University, with a prolific career in cancer research. Catharina Svanborg, MD, Ph.D., is a distinguished figure in the field of clinical immunology. Since obtaining her MD in 1974 and Ph.D. in 1978, she has held the position of Professor of Clinical Immunology at Lund University since 1989. Recognized for her influential research, she has built astrong global reputation. In 1996, Svanborg was elected a Fellow of the Royal Swedish Academy of Science. Throughout her career, she has held notable positions, including a visiting Professorship at Imperial College from 1979 to 1980 and serving as Principal Investigator at the Singapore Immunology Network from 2008 to 2010. Her accolades include the Domagk award, the Kennedy Visiting Professorship Award, and the Scientist of the Year Award in 2014. Svanborg's prolific contributions are evident in her 400+ published papers, and she has mentored numerous graduate students and postdoctoral fellows, many of whom have gone on to successful careers.
👥 Co-hosted by MSQ Ventures and BioAroundWorld, this event promises valuable insights into the future of cancer treatment.
Guest Speaker: Dr. Catharina Svanborg, Founder & Chairman of the Board of Hamlet BioPharma
Moderator: Marc Estigarribia, Managing Director, MSQ Ventures
Date: Wednesday, January 10th, 2024
Time: 9pm – 10pm BJT / 8am – 9am ET
Can’t attend live? Register anyway, and we’ll send you the session recording after the event. Following the webinar, attendees will also have the chance to schedule a one-on-one session with Hamlet BioPharma through MSQ.